thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Drug Discovery questions

Question 10 of 20 Intermediate Troubleshooting

How would you distinguish assay interference from a real hit in an early screening campaign?

Short answer

Test whether the activity survives changes that should not matter. Run a different detection technology, add detergent to break up colloidal aggregates, check the compound's own optical properties, look at the steepness of the curve, and confirm binding by a label-free biophysical method.

Why

Interference has a few recurring mechanisms. Colloidal aggregates form above a critical concentration and sequester enzymes nonspecifically. McGovern and colleagues showed this is a real physical mechanism rather than a vague label, and Feng and colleagues built high-throughput tests for it.

The classic signature is steep inhibition curves, sensitivity to a small amount of nonionic detergent, and dependence on enzyme concentration. Optical interference is just as common. A fluorescent or strongly absorbing compound distorts a fluorescence readout, and firefly luciferase is inhibited by a few percent of typical libraries.

Chemically reactive compounds modify the protein. Baell and Holloway's PAINS substructure filters flag classes that appear as frequent hitters across many unrelated screens, and they emphasize that such compounds are increasingly reported as starting points when they should not be. A filter is a flag, not a verdict, and some flagged scaffolds are genuine.

The decisive evidence is agreement across methods that fail in different ways.

How to work it through

  1. Repeat the assay with 0.01 percent nonionic detergent and at a different enzyme concentration to test for aggregation.
  2. Read the compound alone in the detection channel to measure its own fluorescence, absorbance or luminescence quenching.
  3. Rerun the activity in an orthogonal format with a different label or a label-free readout.
  4. Inspect the concentration-response curve for an unusually steep Hill slope and for incomplete plateaus.
  5. Confirm direct binding by a biophysical method such as surface plasmon resonance, isothermal titration calorimetry or a thermal shift.
  6. Check the structure against PAINS and reactive-group filters and look up the compound's history as a frequent hitter.

An example

A screening hit gives an IC50 of 2 micromolar in a fluorescence enzyme assay. Adding detergent shifts it to above 100 micromolar and the Hill slope was 4.2, both pointing to aggregation. A second compound from the same plate keeps its 400 nanomolar potency with detergent, shows a Hill slope near 1, binds the target by surface plasmon resonance with a consistent affinity, and shows a thermal shift.

The second compound goes forward.

Where the answer stops holding

Detergent sensitivity is suggestive but not proof, since some real binders are also affected. Biophysical confirmation needs purified protein and enough compound, and weak binders can fall below the detection limit. A compound can be both a genuine binder and an interferer at higher concentrations.

Filters such as PAINS were derived in particular assay formats and produce false alarms, so they should trigger extra testing rather than automatic rejection.

A strong answer covers

  • Detergent and enzyme concentration test for aggregation
  • Measure the compound's own optical signal
  • Orthogonal detection technology
  • Steep Hill slopes as a warning sign
  • Biophysical confirmation of direct binding

Common mistakes

  • Rejecting a compound solely because it matches a PAINS substructure
  • Confirming a hit in a second assay that uses the same detection chemistry
  • Ignoring a Hill slope far above 1 because the potency looked attractive